During the past decade, Ospedale Policlinico Giambattista Rossi, Borgo Roma conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 8 clinical trials were completed, i.e. on average, 72.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 6 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ospedale Policlinico Giambattista Rossi, Borgo Roma" #1 sponsor was "Eli Lilly and Company" with 7 trials, followed by "Camurus AB" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "Sierra Oncology, Inc." with 2 trials sponsored and "Loxo Oncology, Inc." with 2 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ospedale Policlinico Giambattista Rossi, Borgo Roma" #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Ospedale Policlinico Giambattista Rossi, Borgo Roma" are "Atopic Dermatitis" (3 trials), "Acromegaly" (2 trials), "Cardiovascular Disease" (2 trials), "Chronic Lymphocytic Leukemia" (1 trials) and "Metastatic Pancreatic Cancer" (1 trials). Many other conditions were trialed in "Ospedale Policlinico Giambattista Rossi, Borgo Roma" in a lesser frequency.

Most popular intervention types in "Ospedale Policlinico Giambattista Rossi, Borgo Roma" are "Drug" (14 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Baricitinib" (4 trials), "CAM2029 (octreotide subcutaneous depot)" (2 trials), "bococizumab (PF-04950615)" (2 trials) and "Adalimumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ospedale Policlinico Giambattista Rossi, Borgo Roma" are 14 trials for "All" genders.

Currently, there are NaN active trials in "Ospedale Policlinico Giambattista Rossi, Borgo Roma". undefined are not yet recruiting, 2 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Ospedale Policlinico Giambattista Rossi, Borgo Roma, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Ospedale Policlinico Giambattista Rossi, Borgo Roma, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Ospedale Policlinico Giambattista Rossi, Borgo Roma has several departments that took part in Clinical trials: "Policlinico 'G.B.Rossi' Borgo Roma - A.O.U. Integrata (Giampaolo Tortora)- Oncologia Medica" - 3 trials